
News|Videos|November 16, 2023
Advancements in Relapsed/Refractory DLBCL: An Evolving Landscape
Author(s)Matthew A. Lunning, DO, FACP
A glimpse into the ever-changing treatment landscape of DLBCL, exploring frontline therapy options and the potential for tailoring treatments based on novel agents and randomized trials.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5










































